The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new treatment combinations improve outcomes in TP53 mutant AML?
How could new treatment combinations improve outcomes in TP53 mutant AML?
Daver begins by discussing a recent study that analyzed patients on hypomethylating agents (HMA) versus cytarabine based regimens. He highlights that HMA based therapy maintained better response rates regardless of TP53 variant allele frequency, unlike the cytrabine regimen. He goes on to outline further HMA regimens, such as combinations with venetoclax. He then discusses immune therapies such as magrolimab and their outcomes. Finally, he explains the results of the recent study using APR-246 and the promising activity of natural killer (NK) and NK CAR-T cell based therapies.